Table 2.
Histologic, virologic, and biochemical responses of telbivudine-treated patients at the time of long-term biopsy
| Response rates, n (%) | |
|---|---|
| Liver inflammation response | N = 57 |
| Baseline Knodell necroinflammatory score ≥4/ ≤3 | 48/57 (84)/9/57 (16) |
| Absence/minimal inflammation in liver biopsya | 56/57 (98) |
| Mean (SD) change from the baseline in the Knodell necroinflammatory score | −6.3 (2.8) |
| Knodell necroinflammatory score ≤3 in patients with a baseline score ≥4, n (%) | 47/48 (98) |
| Liver fibrosis response | N = 57 |
| Baseline Ishak fibrosis score ≥1 | 55/57 (96.5) |
| Baseline Ishak fibrosis score ≥2/ ≤1 | 43/57 (75)/14/57 (25) |
| Absence/minimal fibrosis in liver biopsyb, n (%) | 48/57 (84) |
| Mean (SD) change from baseline in the Ishak fibrosis score | −1.3 (1.3) |
| ≥1-point decrease in patients with baseline score ≥1, n (%) | 44/55 (80) |
| ≥1-point decrease in patients with baseline score ≥2, n (%) | 36/43 (84) |
| Virologic, serologic, and biochemical responses | N = 66 |
| Serum HBV DNA <300 copies/mL, n (%) | 66/66 (100) |
| Cumulative HBeAg loss, n (%) | 38/43 (88) |
| Cumulative HBeAg seroconversion, n (%) | 33/43 (77) |
| Cumulative HBsAg loss, n (%) | 4/66 (6) |
| Cumulative HBsAg seroconversion, n (%) | 3/66 (5) |
SD standard deviation, ULN upper limit of normal, HBeAg hepatitis B e antigen, HBV hepatitis B virus
aDefined as Knodell necroinflammatory score ≤3
bDefined as Ishak score ≤1